Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 93.1% in February

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the recipient of a large drop in short interest in February. As of February 15th, there was short interest totalling 1,390,000 shares, a drop of 93.1% from the January 31st total of 20,140,000 shares. Based on an average daily trading volume, of 72,300 shares, the days-to-cover ratio is presently 19.2 days. Currently, 17.9% of the shares of the company are short sold.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Velan Capital Investment Management LP purchased a new position in Karyopharm Therapeutics in the 4th quarter worth $27,000. Focus Partners Wealth purchased a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at about $31,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth about $32,000. Two Sigma Advisers LP grew its stake in shares of Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after purchasing an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP purchased a new position in Karyopharm Therapeutics during the 4th quarter valued at about $85,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Trading Down 4.8 %

Shares of Karyopharm Therapeutics stock traded down $0.40 on Friday, reaching $7.95. The stock had a trading volume of 120,796 shares, compared to its average volume of 78,403. The business’s 50 day moving average is $9.85 and its two-hundred day moving average is $11.28. Karyopharm Therapeutics has a 1 year low of $7.61 and a 1 year high of $25.50. The company has a market cap of $66.94 million, a P/E ratio of -7.79 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) EPS for the quarter, topping the consensus estimate of ($3.90) by $0.30. The business had revenue of $30.54 million for the quarter, compared to analysts’ expectations of $30.29 million. On average, equities analysts anticipate that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KPTI. HC Wainwright boosted their price target on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler lifted their target price on shares of Karyopharm Therapeutics from $60.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $62.75.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).